By a News Reporter-Staff News Editor at Health& Medicine Week A patent application by the inventors Clerc, Claude O.; Weitzner, Barry, filed on March 27, 2014, was made available online on August 7, 2014, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to Boston Scientif
By a News Reporter-Staff News Editor at Health& Medicine Week A patent application by the inventors Lutgen, Gerald; Valdivia, Tomas; Van Vorst, Krista; Bock, Adam, filed on February 3, 2014, was made available online on August 7, 2014, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application
ALEXANDRIA, Va., Aug. 22 Alnylam Pharmaceuticals, Cambridge, Massachusetts, has been assigned a patent developed by six co-inventors for "compositions and methods for inhibiting expression of the PCSK9 gene." The co-inventors are Pamela Tan, Kulmbach, Germany, Birgit Bramlage, Kulmbach, Germany, Maria Frank-Kamenetsky, Brookline, Massachusetts, K
Jonathan Goldman, CEO, Aptuit, said, "The expanded large molecule capability enhances our early development support for the fastest growing sector of the pharmaceutical industry and provides our scientists with the ability to identify active and/or high percentage metabolites in drugs as outlined in the United States Food and Drug Administration...
ALEXANDRIA, Va., Aug. 22 Aventis Pharmaceuticals, Bridgewater, New Jersey, has been assigned a patent developed by Ralf Rosskamp, Gladstone, New Jersey, and Hertzel Gerstein, Hamilton, Canada, for a "method for reducing cardiovascular morbidity and mortality in prediaetic patients and patients with type 2 diabetes." The patent application was fil
By a News Reporter-Staff News Editor at Health& Medicine Week Barrack, Rodos& Bacine is investigating possible violations of the federal securities law, including unlawful insider trading, on behalf of purchasers of Galectin Therapeutics, Inc. securities between July 9, 2013 and July 28, 2014. On July 9, 2013, Galectin CEO Peter Traber appeared o
Aug. 21 Baxter International Inc. said Thursday a key hemophilia drug under development met its primary goal in a late-stage clinical study. It is partnering with San Francisco- based Nektar Therapeutics on development of the treatment. About 20,000 Americans suffer from the disorder, according to the National Hemophilia Foundation.
'CoLucid Pharmaceuticals, Inc.- Product Pipeline Review- 2014', provides an overview of the CoLucid Pharmaceuticals, Inc.' s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of CoLucid Pharmaceuticals, Inc.' s, complete with comparative analysis at variou
'Haemostatix Ltd- Product Pipeline Review- 2014', provides an overview of the Haemostatix Ltd's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Haemostatix Ltd's, complete with comparative analysis at various stages, therapeutics assessment by drug...
ALEXANDRIA, Va., Aug. 22 Cerulean Pharma, Cambridge, Massachusetts, has been assigned a patent developed by J. Michael Ramstack, Lunenburg, Massachusetts, and John Podobinski, Boston, for a "method for fabricating nanoparticles." The patent application was filed on Sept. 10, 2013. Written by Sudarshan Harpal; edited by Jaya Anand.
Nanotherapeutics, Inc. is a privately held biopharmaceutical company with a major focus on developing a diversified proprietary pipeline of products having both biodefense and medical applications. Products under development include biodefense medical countermeasures, CNS, wound healing, addiction and pain, oncology, anti-infectives, vaccines and..
Cubist Pharmaceuticals, Inc. today announced that the European Medicines Agency has accepted for review the Company s Marketing Authorization Application for its investigational antibiotic ceftolozane/tazobactam. These studies met both the EMA and U.S. Food and Drug Administration specified primary endpoints. Prior to the EMA acceptance of the M
Easton Pharmaceuticals Inc. a specialty pharmaceutical company that owns, designs, develops, and markets an array of topically-delivered drugs and therapeutic/ cosmetic healthcare products, today announces financing update, provides due diligence documents towards financing from a Toronto, Canada, based brokerage firm. Easton Pharmaceuticals has ov
ALEXANDRIA, Va., Aug. 22 Enanta Pharmaceuticals, Watertown, Massachusetts, has been assigned a patent developed by nine co-inventors for "quinoxalinyl macrocyclic hepatitis C virus serine protease inhibitors." The co-inventors are Deqiang Niu, Lexington, Massachusetts, Dong Liu, Waltham, Massachusetts, Joel D. Moore, Lexington, Massachusetts, Guo
For generic drugmakers, Oct. 1 is crunch time and is the date after which all ANDA amendment and prior-approval supplement applications must meet new performance goals under the Generic Drug User Fee Amendments of 2012.. Attendees will discover concrete examples that illustrate what ANDA sponsors can expect and must prepare for. Here's a point-by-p
An increasing number of mergers and acquisitions is one of the potential trends emerging in the market. The Global Animal Health market covers the following segments: Feed Additives, Pharmaceuticals, Vaccines, and Diagnostics. This report covers the present scenario and the growth prospects of the Global Animal Health market for the period 2014-201
Despite a few guidance documents to help sponsors prepare for meetings with the FDA, it is a challenge to understand the most efficient and productive ways to strategize, prepare, conduct, and follow-up for these meetings. This one-of-a-kind workshop will provide step-by-step instructions and practical tips to the most productive meeting with FDA f
ALEXANDRIA, Va., Aug. 22 Infinity Pharmaceuticals, Cambridge, Massachusetts, has been assigned a patent developed by five co-inventors for "processes for preparing isoquinolinones and solid forms of isoquinolinones." The co-inventors are Pingda Ren, San Diego, Michael Martin, San Marcos, California, Paul Isbester, Castleton, New York, Benjamin S.
Mr. Hill has held a number of senior executive roles in the pharmaceutical industry, including President of InVentiv Clinical, CEO and member of the Board of Directors of PPD, and President of IMS Consulting Group. Earlier on in his career, Mr. Hill was a partner at A.T. Kearney and a consultant at Booz Allen %7 E Hamilton. x0D;. Steven Victor, r
The global eClinical solutions market is broadly categorized into two segments, namely, products and professional services. The products segment is further classified into clinical data management system/electronic data capture, clinical trial management systems, electronic clinical outcome assessment, randomization and trial supply management,...
ALEXANDRIA, Va., Aug. 22 Millennium Pharmaceuticals, Cambridge, Massachusetts, has been assigned a patent developed by four co-inventors for the "inhibitors of NEDD8-activating enzyme." The co-inventors are Ashley Sue McCarron, Bedford, New Hampshire, Todd B. Sells, Southborough, Massachusetts, Matthew Stirling, Randolph, Massachusetts, and Steph
New Medicare and Medicaid Findings Has Been Reported by Investigators at Harvard University. By a News Reporter-Staff News Editor at Insurance Weekly News Investigators publish new report on Medicare and Medicaid. According to news reporting out of Boston, Massachusetts, by VerticalNews editors, research stated, "A' chiral switch' occurs in the..
New Social Science and Medicine Findings from Dalhousie University Reported. Findings are based on fifty semi-structured interviews with medical students in the United States and Canada conducted between 2010 and 2013. ". Our news journalists obtained a quote from the research from Dalhousie University, "Participant responses support the survey-bas
According to news reporting originating from Dortmund, Germany, by NewsRx correspondents, research stated, "Despite intense efforts in pharmaceutical industry and academia, a therapeutic grip on oncogenic Ras proteins has remained elusive. For more information on this research see: Small-molecule modulation of Ras signaling. Nature Chemical Biology
By a News Reporter-Staff News Editor at Health& Medicine Week From Washington, D.C., NewsRx journalists report that a patent application by the inventors Day, Thomas E.; Erbe, Erik M.; Jung, Steven B., filed on March 27, 2014, was made available online on August 7, 2014. No assignee for this patent application has been made. News editors obtained